视网膜血管性疾病（Retinal Vascular Diseases，RVD）是全球主要致盲疾病之一，给患者的生活质量带来了极大的负面影响，同时也加重了社会的医疗负担。随着人口老龄化以及糖尿病、高血压等慢性疾病发病率的上升，RVD的患病率呈现逐年增长的趋势。其中年龄相关性黄斑变性（Age-Related Macular Degeneration，AMD）、糖尿病性黄斑水肿（Diabetic Macular Edema，DME）和视网膜静脉阻塞（Retinal Vein Occlusion，RVO）是最为常见的类型。Faricimab由罗氏公司的CrossMAB平台研发，是一种能够同时靶向并抑制血管内皮生长因子 - A（Vascular Endothelial Growth Factor - A，VEGF - A）和血管生成素 - 2（Angiopoietin - 2，Ang - 2）的新型双特异性单抗。Faricimab对这两个关键因子的双重抑制，使其具备了更全面、更有效地调节血管生成和炎症反应的潜力，为RVD的治疗带来了新的契机。

Retinal Vascular Diseases (RVD) is one of the major blinding diseases globally. It has a significant negative impact on the quality of life of patients and also exacerbates the social medical burden. With the aging of the population and the increasing incidence of chronic diseases such as diabetes and hypertension, the prevalence of RVD shows a trend of increasing year by year. Among them, Age - Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), and Retinal Vein Occlusion (RVO) are the most common types.